Last Updated: July 28, 2026

Suppliers and packagers for LOW-OGESTREL-21


✉ Email this page to a colleague

« Back to Dashboard


LOW-OGESTREL-21

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Dr Reddys Labs Sa LOW-OGESTREL-21 ethinyl estradiol; norgestrel TABLET;ORAL-21 075288 ANDA Mayne Pharma Inc. 51862-564-06 6 BLISTER PACK in 1 CARTON (51862-564-06) / 1 KIT in 1 BLISTER PACK (51862-564-01) 2016-08-03
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug Low-Ogestrel 21: Who Manufactures, Packs, and Supplies the Product

Last updated: June 19, 2026

Low-Ogestrel 21 is a branded version of a combined oral contraceptive containing levonorgestrel and ethinyl estradiol (21 active tablets per cycle). The relevant “suppliers” are the firms that manufacture the drug substance (API), produce the finished dosage form (tablets), and package/distribute the finished product to wholesalers and pharmacies.

No complete, accurate supplier map is available from the information provided. Without a verified product identity (generic label configuration, NDC, dosage strength, manufacturer on the carton/label, and FDA listing) and without source citations tied to that exact NDC, any attempt to name specific companies for API, tablet manufacturing, packaging, or distribution would not meet accuracy requirements.

Which companies supply Low-Ogestrel 21 tablets (NDC-specific)

Featured snippet answer: The supplier set for Low-Ogestrel 21 is determined by the exact NDC and labeler/manufacturer shown on the FDA listing and the current packaging label. Those data are not provided, so supplier names cannot be stated accurately.

What “supplier” means for combination oral contraceptives

For a product like Low-Ogestrel 21, supplier attribution typically splits into:

  • Labeler / finished-goods distributor (who appears as the “labeler” in FDA’s listings)
  • Finished dosage form manufacturer (the site that makes and releases tablets)
  • Packaging / repackaging firms (often separate from tablet manufacturing)
  • API manufacturers for:
    • levonorgestrel
    • ethinyl estradiol

What is the FDA Orange Book status of Low-Ogestrel 21

Featured snippet answer: The Orange Book status and patent/marketing exclusivity do not determine manufacturing suppliers. They identify whether patents and exclusivities are listed for the NDA. Orange Book data require the NDA/NDC mapping for the specific product.

How do I identify the actual manufacturer on Low-Ogestrel 21 packaging

Featured snippet answer: The manufacturer name is typically on the:

  • carton (“Manufactured for…”, “Distributed by…”, “Manufactured by…”)
  • blister/label text (often includes the firm and address)

Those label fields are not provided, and the NDC is not provided, so supplier identification cannot be completed.

Which API suppliers make levonorgestrel and ethinyl estradiol for oral contraceptives

Featured snippet answer: API suppliers for levonorgestrel and ethinyl estradiol are often numerous globally and can vary by finished product NDC and by production lot. A definitive list for Low-Ogestrel 21 requires lot-level or FDA listing-level linkage to specific API vendors, which is not provided.

Which finished-dose manufacturers can legally produce Low-Ogestrel 21

Featured snippet answer: The legal manufacturing entities are the firms listed as manufacturers/labelers for the specific NDC and NDA. Those records must be tied to the exact product identity; no NDC/NDA mapping is provided.

Does Low-Ogestrel 21 have multiple suppliers or just one

Featured snippet answer: Many oral contraceptives have multiple labelers or alternate manufacturing sites across NDCs, label changes, and supply transitions. Whether Low-Ogestrel 21 has multiple suppliers cannot be determined without NDC-level sourcing evidence.

How do distribution channels affect “supplier” attribution

Featured snippet answer: Wholesaler distribution can involve major pharmaceutical distributors, but identifying the correct distributor requires a particular NDC and time window. Distributor identity is not the same as manufacturer identity.

Common distribution vs. manufacturing

  • Manufacturing suppliers are tied to FDA product listings and labeling
  • Distributors/wholesalers are tied to commercial distribution networks and contracting

Key Takeaways

  • Supplier identification for Low-Ogestrel 21 must be anchored to the exact NDC and FDA listing labeler/manufacturer entries.
  • The information provided does not include NDC, NDA, carton/label manufacturer, or FDA listing identifiers, so naming specific API, tablet manufacturing, packaging, or distribution firms would be inaccurate.

FAQs

  1. How can I tell who manufactures Low-Ogestrel 21?
    By matching the NDC to the FDA listing manufacturer/labeler and confirming the carton/label “manufactured for/distributed by/manufactured by” text.

  2. Are API suppliers for levonorgestrel/ethinyl estradiol the same for all Low-Ogestrel 21 lots?
    Not necessarily; API sourcing can change by lot and by finished goods manufacturer site.

  3. What evidence is strongest for identifying Low-Ogestrel 21 manufacturers?
    FDA listing entries tied to the product’s NDC and the manufacturer names shown on the packaged product.

  4. Can wholesalers be mistaken for “suppliers” of Low-Ogestrel 21?
    Yes. Wholesalers distribute; they do not necessarily manufacture or package.

  5. Does Orange Book exclusivity tell me who supplies Low-Ogestrel 21?
    No. Orange Book focuses on patent and exclusivity, not manufacturing site/vendor attribution.

References (APA)

No sources were cited because no validated product identifiers (NDC/NDA/labeler/manufacturer) were provided for Low-Ogestrel 21.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.